Octapharma
Octapharma AG, headquartered in Switzerland (CH), is a leading global player in the biopharmaceutical industry, specialising in the development and production of human proteins derived from human plasma and recombinant technologies. Founded in 1983, Octapharma has established a strong presence in Europe, North America, and Asia, with a commitment to innovation and quality. The company’s core product offerings include a range of immunoglobulins, coagulation factors, and albumin, which are essential for treating various medical conditions, including immune deficiencies and bleeding disorders. Octapharma is renowned for its dedication to patient safety and product efficacy, setting it apart in a competitive market. With a robust pipeline and a focus on research and development, Octapharma has achieved significant milestones, positioning itself as a trusted name in the biopharmaceutical sector, committed to improving patient outcomes worldwide.
DitchCarbon Score
How does Octapharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Octapharma's score of 30 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Octapharma's reported carbon emissions
In 2023, Octapharma reported total carbon emissions of approximately 177,000 kg CO2e, with significant contributions from Scope 1 emissions at about 102,000 kg CO2e, Scope 2 emissions at around 4,000 kg CO2e, and Scope 3 emissions at approximately 71,000 kg CO2e. This marks a reduction from 2022, when total emissions were about 181,000 kg CO2e, and a notable decrease from 2019's total of approximately 236,000 kg CO2e. Since 2019, Octapharma has successfully reduced its overall emissions by 22% and has set an ambitious target to achieve a 30% reduction by 2028. Furthermore, the company is committed to reaching Net Zero emissions by 2050, demonstrating its dedication to sustainable practices and climate responsibility. These initiatives reflect Octapharma's proactive approach to addressing climate change and minimising its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2022 | |
|---|---|---|
| Scope 1 | 73,000 | 00,000 |
| Scope 2 | 7,000 | 0,000 |
| Scope 3 | 156,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Octapharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
